Cepheid
An American molecular diagnostics company known for automated GeneXpert systems and cartridge-based nucleic-acid tests.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Cepheid is an American molecular diagnostics company headquartered in Sunnyvale, California, and operating as a subsidiary of Danaher Corporation. Its business centers on automated molecular testing systems, disposable test cartridges, and assays that detect specific DNA or RNA sequences from clinical and other biological samples. The company’s principal technology platform is GeneXpert, a family of modular instruments that performs sample preparation, nucleic-acid amplification, and target detection in a largely self-contained workflow. By integrating these steps into a cartridge and instrument combination, Cepheid aims to bring molecular testing closer to the patient and to laboratories that may lack the infrastructure required for conventional, highly centralized testing. Cepheid was incorporated in California in March 1996 by Thomas Gutshall, Bill McMillan, Kurt Petersen, Greg Kovacs, Steven Young, and Allen Northrup. Its early technology was connected to microelectromechanical-systems research at Lawrence Livermore National Laboratory, where work supported by the U.S. Defense Advanced Research Projects Agency, the U.S. Army, and laboratory funding helped advance miniaturized and automated nucleic-acid testing. The company initially developed the SmartCycler system, which integrated amplification and detection in a compact instrument. SmartCycler was launched in 2000, the same year Cepheid completed its initial public offering. The company’s strategic importance increased after it adapted its technology for biodefense and public-health applications. Following the 2001 anthrax attacks in the United States, Cepheid worked with Northrop Grumman on a federal program involving anthrax detection systems for U.S. Postal Service sites. Although the company temporarily emphasized defense-related work, its longer-term commercial direction became clinical diagnostics. The GeneXpert platform subsequently became the foundation of Cepheid’s business, combining reusable desktop or modular instruments with single-use cartridges containing reagents and reaction chambers. Customers purchase the cartridges from Cepheid for each test, creating a recurring consumables component alongside instrument sales and service. Cepheid’s clinical portfolio spans infectious diseases, healthcare-associated infections, sexual health, oncology, genetics, and selected respiratory and public-health applications. Representative tests include Xpert MTB/RIF and Xpert MTB/RIF Ultra for tuberculosis and rifampicin resistance, Xpert HIV-1 viral-load and qualitative assays, Xpert HCV and HBV tests, Xpert HPV, Xpert MRSA, Xpert Carba-R, Group B Streptococcus testing, and a range of respiratory and sexually transmitted infection assays. The platform is particularly associated with tuberculosis programs because it can produce molecular results substantially faster than conventional smear and culture workflows and can identify rifampicin resistance, an important marker of possible drug-resistant disease. The COVID-19 pandemic demonstrated the value of Cepheid’s installed instrument base. In March 2020, the U.S. Food and Drug Administration granted emergency use authorization to Xpert Xpress SARS-CoV-2, allowing testing on existing GeneXpert systems in authorized laboratories and certain patient-care settings. Cepheid later expanded its respiratory testing offerings to include combined SARS-CoV-2, influenza, and respiratory syncytial virus testing. The original Xpert Xpress SARS-CoV-2 EUA was revoked at Cepheid’s request on May 28, 2025, after U.S. customers had transitioned to the Xpert Xpress SARS-CoV-2 plus product. Cepheid was acquired by Danaher in November 2016 for approximately $4 billion, including assumed debt and net of acquired cash. The acquisition removed Cepheid from the public markets and placed it within Danaher’s Diagnostics segment. Cepheid remains a distinct operating brand, with Danaher providing corporate ownership and operating-system support w…
History
Cepheid was incorporated in California on March 4, 1996, by Thomas Gutshall, Bill McMillan, Kurt Petersen, Greg Kovacs, Steven Young, and Allen Northrup. The company emerged from a technology environment influenced by microelectromechanical-systems research at Lawrence Livermore National Laboratory. Early development was supported by DARPA, the U.S. Army, and internal laboratory resources. The objective was to simplify the complicated, multi-stage process used to detect and analyze nucleic acids in samples such as blood, urine, food, and industrial water. Cepheid’s first major commercial platform was SmartCycler, a compact system designed to combine nucleic-acid amplification and detection in one instrument. It was launched in 2000, the same year the company became publicly traded. SmartCycler helped establish Cepheid’s expertise in miniaturized real-time PCR, while the company continued developing the more integrated GeneXpert architecture. Cepheid’s mission was not simply to make PCR faster, but to package sample handling, reagent management, amplification, and detection into a workflow that could be used outside highly specialized central laboratories. The company’s path was influenced by national-security events. After the 2001 anthrax attacks in the United States, federal agencies contracted with Cepheid to support anthrax tracking and detection. In 2003, Cepheid temporarily redirected some healthcare-development resources toward a collaboration with Northrop Grumman to install anthrax detection systems at U.S. Postal Service locations. This work demonstrated that the company’s small-footprint molecular technology could be adapted to urgent, distributed testing requirements. John L. Bishop became chief executive officer in April 2002 and remained in the role until the company was acquired in 2016. Under Bishop, Cepheid increasingly focused on clinical molecular diagnostics. The first clinical GeneXpert application, XpertGBS, received U.S. FDA clearance in 2006 for rapid detection of Group B Streptococcus in pregnant women. In August of that year, the FDA classified the test as moderate complexity under the Clinical Laboratory Improvement Amendments. This was significant because the classification allowed use in a much broader set of qualified laboratories than high-complexity molecular testing. Cepheid expanded through both internal development and acquisition. In February 2007 it acquired Sangtec Molecular for approximately $27 million. It also won public-sector contracts, including a 2007 U.S. Department of Veterans Affairs contract for MRSA reagent kits. During this period, the GeneXpert system evolved into the core of the company’s commercial model: reusable instruments would be placed in laboratories and healthcare facilities, while each test would use a manufacturer-supplied, single-use cartridge. The cartridge architecture simplified testing for operators but also made Cepheid the continuing supplier of consumables and assay chemistry. Tuberculosis became one of the most consequential applications of GeneXpert. Cepheid worked with the Foundation for Innovative New Diagnostics, academic researchers, and public-health funders to develop Xpert MTB/RIF, a cartridge that could detect Mycobacterium tuberculosis and provide information about rifampicin resistance in roughly the same testing session. WHO endorsed the technology in December 2010. The assay was subsequently incorporated into tuberculosis programs supported by governments, UNITAID, the Global Fund, PEPFAR, USAID, FIND, and other organizations. The platform was especially valuable for people living with HIV, children, and patients with suspected drug-resistant tuberculosis, for whom conventional diagnostic pathways could be slow or difficult. Affordability became a central issue in the global deployment of GeneXpert. In 2012, a public-private buy-down agreement involving PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation reduced the price of eligible tuberculosis cartridges to approximately $9.98 in 145 countries. UNITAID-supported initiatives such as EXPAND-TB and TBXpert also helped place instruments in lower levels of health systems and expand access beyond national reference laboratories. In 2015, Cepheid and FIND introduced GeneXpert Omni, a proposed portable, battery-operated, wireless, web-enabled platform intended to extend molecular testing closer to the point of care. The company later continued concentrating on scalable GeneXpert configurations rather than replacing the platform with a wholly different architecture. Cepheid broadened its menu beyond tuberculosis into HIV viral load and early-infant diagnosis, hepatitis, HPV, sexually transmitted infections, healthcare-associated infections, respiratory pathogens, oncology, and genetic disorders. In June 2014, it joined AstraZeneca, Cubist Pharmaceuticals, and GSK in a consortium focused on rapid testing for carbapenem-resistant and other multidrug-resistant organisms. The aim was to help clinicians identify resistant pathogens and select antibiotics more appropriately. In September 2016, Danaher agreed to acquire Cepheid for $53 per share, or approximately $4 billion including indebtedness and net of acquired cash. The transaction closed on November 4, 2016. Cepheid ceased to be an independent public company and became part of Danaher’s Diagnostics segment. Danaher described the acquisition as a way to add molecular diagnostics, a large installed instrument base, and recurring test revenue to its healthcare portfolio. The COVID-19 crisis highlighted the installed-base strategy. In March 2020, the FDA granted emergency use authorization to Xpert Xpress SARS-CoV-2, enabling rapid SARS-CoV-2 testing on compatible GeneXpert systems already deployed in hospitals and laboratories. Cepheid subsequently added combined respiratory-virus products and other updated SARS-CoV-2 assays. The original Xpert Xpress SARS-CoV-2 EUA was revoked on May 28, 2025, at Cepheid’s request after U.S. customers moved to the newer Xpert Xpress SARS-CoV-2 plus product. Cepheid’s public-health role continued after the acute COVID-19 period. Its Global Access Program covers tuberculosis, HIV, Ebola, and other high-burden diseases, and in 2023 Danaher announced at-cost supply of Xpert MTB/RIF Ultra cartridges to the Global Fund and eligible less-developed countries. On October 25, 2024, WHO listed Xpert Mpox under its Emergency Use Listing procedure. Cepheid therefore remains an active Danaher brand whose history combines defense technology, decentralized molecular testing, infectious-disease control, recurring cartridge economics, and partnerships aimed at expanding access to diagnostics.
- 2025
Original SARS-CoV-2 EUA is revoked
[11]The FDA revokes the original Xpert Xpress SARS-CoV-2 EUA at Cepheid’s request after U.S. customers transition to the plus version.
- 2024
WHO lists Xpert Mpox
[12]WHO lists Cepheid’s Xpert Mpox real-time PCR assay under its Emergency Use Listing procedure.
- 2023
At-cost tuberculosis access commitment
[3]Danaher announces at-cost supply of Xpert MTB/RIF Ultra cartridges to the Global Fund and eligible less-developed countries through Cepheid’s Global Access Program.
- 2020
Xpert Xpress SARS-CoV-2 receives FDA emergency authorization
[9]The FDA authorizes Xpert Xpress SARS-CoV-2 for use on compatible GeneXpert systems in authorized laboratories and certain point-of-care settings.
- 2016
Danaher completes acquisition
[8]Danaher completes its acquisition of Cepheid on November 4, 2016, bringing the company into Danaher’s Diagnostics segment.
- 2015
GeneXpert Omni announced
[19]Cepheid and FIND unveil GeneXpert Omni, a proposed portable, battery-operated and connected molecular-testing platform for near-patient use.
- 2014
Antimicrobial-resistance collaboration
[15]Cepheid joins AstraZeneca, Cubist Pharmaceuticals, and GSK in a consortium to develop rapid tests for multidrug-resistant pathogens.
- 2012
Global tuberculosis cartridge price reduction
[13]International donors negotiate a buy-down arrangement that lowers the eligible-country price of GeneXpert tuberculosis cartridges to approximately $9.98 per test.
- 2010
WHO endorses Xpert MTB/RIF
[13]WHO endorses the GeneXpert-based Xpert MTB/RIF assay for tuberculosis and rifampicin-resistance testing.
- 2007
Sangtec Molecular acquisition
[1]Cepheid acquires Sangtec Molecular for approximately $27 million.
Products and positioning
High-performance, automated molecular diagnostics designed to deliver rapid testing near the patient while scaling from small laboratories to large, high-throughput facilities.
Molecular diagnostic system
GeneXpert
GeneXpert is Cepheid’s principal family of automated molecular diagnostic instruments. The system uses single-use cartridges that contain the sample-processing chambers, reagents, valves, and reaction components required for nucleic-acid testing. Instruments automate sample preparation, amplification, and optical detection, reducing the number of manual steps and allowing molecular assays to be performed in laboratories, hospitals, and other near-patient environments. The platform is available in multiple modular configurations, supporting applications ranging from small testing sites to higher-throughput facilities.
High-throughput molecular diagnostic system
GeneXpert Infinity
GeneXpert Infinity systems extend the GeneXpert architecture to larger laboratories and centralized testing environments. They are designed to process multiple cartridges with a high degree of automation and to support broad assay menus across infectious disease, sexual health, oncology, genetics, and other clinical categories. Infinity systems retain the cartridge-based workflow while increasing capacity and reducing hands-on intervention compared with smaller desktop configurations.
Near-patient molecular diagnostic system
GeneXpert Xpress
GeneXpert Xpress configurations are intended for rapid testing closer to the point of care. They use the same general cartridge-based molecular approach as other GeneXpert systems but are designed for simplified operation in settings such as hospitals, urgent-care environments, and decentralized laboratories. The Xpress platform became especially visible during the COVID-19 pandemic because compatible systems could run Cepheid’s rapid SARS-CoV-2 assays.
Tuberculosis molecular assay · 2017
Xpert MTB/RIF Ultra
Xpert MTB/RIF Ultra is a cartridge-based real-time PCR assay for detecting Mycobacterium tuberculosis complex and mutations associated with rifampicin resistance. It is designed for use with GeneXpert systems and has been central to global tuberculosis-control programs because it can provide molecular results much faster than conventional culture-based workflows. The assay is included in Cepheid’s Global Access Program and is supplied at cost to selected public-health customers and eligible countries under Danaher’s access commitment.
Respiratory molecular assay · 2022
Xpert Xpress SARS-CoV-2 plus
Xpert Xpress SARS-CoV-2 plus is a molecular assay for detecting SARS-CoV-2 on compatible GeneXpert systems. It followed the original Xpert Xpress SARS-CoV-2 product and became the product to which U.S. customers transitioned after the original assay’s EUA was revoked in 2025. The test is part of Cepheid’s respiratory-virus portfolio and is intended to provide rapid molecular results in authorized laboratory and patient-care settings, subject to applicable regulatory status.
Multiplex respiratory molecular assay · 2020
Xpert Xpress SARS-CoV-2/Flu/RSV
Xpert Xpress SARS-CoV-2/Flu/RSV is a multiplex molecular test designed to detect and differentiate SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus nucleic acids. It uses the GeneXpert workflow to provide a consolidated respiratory-pathogen result from a clinical specimen. The U.S. FDA issued an EUA for the product in 2020, although that EUA was later revoked in 2023 as regulatory and product-generation conditions changed.
Mpox molecular assay · 2024
Xpert Mpox
Xpert Mpox is a real-time PCR assay for qualitative detection of monkeypox virus clade II and non-variola Orthopoxvirus DNA in lesion-swab specimens from individuals suspected of mpox. The assay is designed for use on compatible GeneXpert systems. WHO listed Xpert Mpox under its Emergency Use Listing procedure in October 2024, expanding the availability of quality-assured molecular testing options during mpox outbreaks.
HIV molecular assay
Xpert HIV-1 Viral Load
Xpert HIV-1 Viral Load is a GeneXpert-based assay for measuring HIV-1 RNA, supporting treatment monitoring and clinical management. Its integration into an automated cartridge system is intended to make viral-load testing more accessible in laboratories that may not operate the large centralized platforms traditionally associated with molecular virology. Cepheid also offers related HIV qualitative and early-infant-diagnosis applications in selected markets.
Human papillomavirus molecular assay
Xpert HPV
Xpert HPV is a molecular assay for detecting high-risk human papillomavirus DNA and identifying clinically relevant HPV genotypes or genotype groups. The assay supports cervical-cancer screening and triage workflows and uses the automated GeneXpert cartridge format. By combining sample processing and molecular detection in one system, it can be used in laboratories that need scalable HPV testing without building a highly manual PCR workflow.
Antimicrobial-resistance molecular assay · 2014
Xpert Carba-R
Xpert Carba-R is a molecular assay designed to detect genetic markers associated with carbapenem resistance in selected bacterial organisms. It emerged from Cepheid’s work with pharmaceutical companies and public-health partners on rapid diagnosis of multidrug-resistant infections. The test is intended to support infection-control decisions, surveillance, and more informed antimicrobial management by providing resistance-marker information faster than many conventional culture and susceptibility workflows.
Legacy real-time PCR system · 2000
SmartCycler
SmartCycler was Cepheid’s early compact molecular testing system and one of the company’s first commercial platforms. It integrated amplification and detection in a relatively small instrument, helping demonstrate the feasibility of decentralized real-time PCR. Although GeneXpert became Cepheid’s principal commercial platform, SmartCycler remains an important part of the company’s technology history and has been used in specialized settings, including research and spaceflight-related applications.
Marketing campaigns
- 2023Cepheid Global Access Program
Eligible low- and middle-income countries · Global Fund-supported programs · Countries affected by TB, HIV, Ebola, and other high-burden diseases
Cepheid’s Global Access Program is an access initiative for high-burden diseases. In 2023, Danaher announced that Cepheid would provide Xpert MTB/RIF Ultra cartridges at cost to the Global Fund and eligible less-developed countries, with no profit to Cepheid or Danaher on those designated supplies.
Outcome. The program formalized a continuing access model for selected public-health customers and expanded the availability of tuberculosis testing in resource-constrained settings.
- 2020COVID-19 rapid-testing response
United States · Worldwide
During the COVID-19 emergency, Cepheid developed and distributed SARS-CoV-2 molecular tests designed to run on the installed GeneXpert base. The strategy used existing instruments in hospitals and laboratories rather than requiring an entirely new testing infrastructure.
Outcome. The FDA granted emergency use authorization to Xpert Xpress SARS-CoV-2 in March 2020, and Cepheid subsequently expanded its respiratory testing range.
- 2014Carbapenem Resistance Consortium
Worldwide clinical and public-health markets
Cepheid partnered with AstraZeneca, Cubist Pharmaceuticals, and GSK to develop rapid diagnostics for multidrug-resistant bacterial infections, initially focusing on carbapenem-resistance detection and the appropriate use of antibiotics.
Outcome. The collaboration supported development and promotion of rapid resistance testing, including work associated with Xpert Carba-R.
- 2012GeneXpert TB cartridge buy-down
145 eligible high-burden and developing countries
PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation negotiated a public-private price-reduction arrangement with Cepheid for GeneXpert tuberculosis cartridges. The arrangement was intended to reduce the affordability barrier to molecular TB testing in countries with substantial disease burdens.
Outcome. The negotiated eligible-country price was reduced to approximately $9.98 per cartridge, supporting broader public-sector deployment.
- 2009EXPAND-TB
High-burden tuberculosis countries · Africa · Asia · Latin America
EXPAND-TB was a UNITAID-funded initiative involving international tuberculosis partners that expanded access to newer diagnostic technologies, including GeneXpert-related testing, in endemic countries. The program focused on strengthening laboratory networks and moving testing capacity beyond national reference laboratories.
Outcome. The initiative helped create demand and implementation capacity for rapid molecular tuberculosis testing in multiple high-burden settings.
Brand decisions
2024
Advance Xpert Mpox through WHO emergency listingProduct launchBackground
The 2024 mpox public-health emergency increased demand for quality-assured molecular tests capable of detecting viral DNA from lesion specimens.
Action taken
Cepheid submitted Xpert Mpox for emergency review, and WHO listed the assay on October 25, 2024, for compatible GeneXpert systems.
Aftermath
Xpert Mpox became an additional internationally recognized molecular-testing option for mpox outbreak response and surveillance.
2023
Provide selected tuberculosis cartridges at costOtherBackground
Affordability remained a constraint on tuberculosis testing in lower-income and high-burden settings despite the long-standing GeneXpert installed base.
Action taken
Danaher announced that Cepheid would supply Xpert MTB/RIF Ultra cartridges at cost to the Global Fund and eligible countries under the Global Access Program.
Aftermath
The commitment strengthened Cepheid’s public-health access strategy and was intended to remove profit from designated tuberculosis cartridge supplies.
2020
Rapidly adapt GeneXpert for SARS-CoV-2 testingProduct launchBackground
The COVID-19 emergency created immediate demand for rapid molecular testing, while hospitals and laboratories already operated thousands of GeneXpert instruments.
Action taken
Cepheid developed Xpert Xpress SARS-CoV-2 for use on compatible GeneXpert systems and sought emergency authorization from the FDA.
Aftermath
The FDA issued an EUA on March 21, 2020, describing it as the first point-of-care COVID-19 diagnostic authorized by the agency. The original EUA was later revoked on May 28, 2025, after transition to the plus product.
2016
Sell Cepheid to DanaherM&ABackground
Cepheid had built a substantial molecular-diagnostics installed base and recurring cartridge business but remained an independent public company in a consolidating diagnostics industry.
Action taken
Cepheid’s board approved Danaher’s cash offer of $53 per share, and Danaher completed the acquisition on November 4, 2016.
Aftermath
Cepheid became a Danaher Diagnostics subsidiary and ceased trading as an independent Nasdaq-listed company. Danaher applied its operating system and integrated Cepheid into its broader diagnostics portfolio.
Cepheid acquisition value. Approximately $4.0 billion including assumed debt and net of acquired cash (Announced September 6, 2016; completed November 4, 2016)
2014
Build an antimicrobial-resistance diagnostics partnershipStrategyBackground
Rising antimicrobial resistance created demand for rapid tests that could identify resistant organisms and improve antibiotic selection.
Action taken
Cepheid formed a collaboration with AstraZeneca, Cubist Pharmaceuticals, and GSK focused on rapid detection of multidrug-resistant pathogens.
Aftermath
The partnership reinforced Cepheid’s strategy of combining molecular diagnostics with pharmaceutical and public-health initiatives, including work associated with Xpert Carba-R.
2012
Accept a donor-backed price reduction for tuberculosis cartridgesOtherBackground
The cost of GeneXpert cartridges was identified as a barrier to tuberculosis testing in high-burden and lower-income countries.
Action taken
Cepheid entered a buy-down arrangement with PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation that reduced the eligible-country cartridge price.
Aftermath
The arrangement helped expand public-sector access and supported broader deployment of GeneXpert systems through international tuberculosis programs.
Eligible-country Xpert MTB/RIF cartridge price. Approximately $16.68 per test → Approximately $9.98 per test (2012 onward under the negotiated arrangement)
2010
Prioritize tuberculosis as a global molecular-diagnostics applicationProduct launchBackground
Tuberculosis programs needed faster detection and drug-resistance information, particularly for people living with HIV and patients at risk of multidrug-resistant disease.
Action taken
Cepheid, FIND, academic researchers, and public funders developed and scaled Xpert MTB/RIF on GeneXpert systems.
Aftermath
WHO endorsed the technology in December 2010, and international donors supported large-scale deployment and price reductions in eligible countries.
2006
Move GeneXpert technology into clinical diagnosticsProduct launchBackground
Cepheid needed to convert its automated molecular-testing technology from research, industrial, and biodefense uses into regulated clinical applications.
Action taken
The company introduced XpertGBS as its first clinical GeneXpert application and pursued FDA clearance and CLIA categorization.
Aftermath
The moderate-complexity classification broadened the number of qualified laboratories able to perform the test and established a path for later GeneXpert clinical assays.
2003
Temporary shift toward biodefense testingStrategyBackground
After the 2001 anthrax attacks, U.S. federal demand for rapid biological-threat detection increased. Cepheid had to balance its emerging clinical-diagnostics business with a major government biodefense opportunity.
Action taken
Cepheid temporarily placed some healthcare development on hold and worked with Northrop Grumman on anthrax detection systems for U.S. Postal Service facilities.
Aftermath
The program demonstrated the adaptability of Cepheid’s compact molecular technology and contributed to the company’s broader reputation for responding to urgent public-health and biosecurity needs.
Recent events
- 2025
FDA revokes the original Xpert Xpress SARS-CoV-2 EUA at Cepheid’s request[11]
Regulation · Product generation
The FDA revoked the original EUA for Xpert Xpress SARS-CoV-2 after Cepheid requested withdrawal because U.S. customers had transitioned to the Xpert Xpress SARS-CoV-2 plus product.
- 2024
WHO lists Xpert Mpox for emergency use[12]
Product launch · Regulation
WHO listed Cepheid’s Xpert Mpox real-time PCR assay under its Emergency Use Listing procedure for compatible GeneXpert systems.
- 2023
Danaher expands at-cost access to tuberculosis cartridges[3]
Pricing · Campaign
Danaher announced that Cepheid would supply Xpert MTB/RIF Ultra cartridges at cost to the Global Fund and eligible countries through its Global Access Program.
- 2020
FDA grants EUA to Xpert Xpress SARS-CoV-2[9]
Product launch · Regulation
The FDA authorized Cepheid’s Xpert Xpress SARS-CoV-2 test for use in high- and moderate-complexity laboratories and certain point-of-care settings during the COVID-19 emergency.
- 2016
Danaher announces agreement to acquire Cepheid[7]
M&A
Danaher announced a cash acquisition of Cepheid at $53 per share, valuing the transaction at approximately $4 billion including indebtedness and net of acquired cash.
- 2014
Cepheid and pharmaceutical companies form antimicrobial-resistance consortium[15]
Campaign · Product launch
Cepheid partnered with AstraZeneca, Cubist Pharmaceuticals, and GSK to develop rapid diagnostics for multidrug-resistant bacterial infections and support more appropriate antibiotic use.
- 2012
Global partners support lower-cost GeneXpert tuberculosis testing[13]
Pricing · Campaign
PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation negotiated a buy-down arrangement that reduced the price of eligible GeneXpert tuberculosis cartridges in high-burden and developing countries.
- 2007
Cepheid acquires Sangtec Molecular[1]
M&A
Cepheid acquired Sangtec Molecular, expanding its molecular-diagnostics capabilities and test-development portfolio.
- 2007
U.S. Department of Veterans Affairs selects Cepheid MRSA tests[1]
Other
Cepheid won a contract with the U.S. Department of Veterans Affairs for MRSA reagent test kits, supporting the use of molecular screening in the federal healthcare system.
- 2006
FDA clears XpertGBS for Group B Streptococcus testing[1]
Product launch · Regulation
XpertGBS became Cepheid’s first clinical GeneXpert application and was later categorized by the FDA as a moderate-complexity molecular test under CLIA.
Showing the 10 most recent.
Sources20 sources
- 1Cepheid (company), Wikipediaen.wikipedia.org
- 2Cepheid mission and historycepheid.com
- 3Cepheid Global Access Programcepheid.com
- 4Cepheid leadership: Vitor Rochacepheid.com
- 5Cepheid leadership: Ephraim Tsalikcepheid.com
- 6Cepheid leadership: Anne Beauburncepheid.com
- 7Danaher announces acquisition of Cepheidinvestors.danaher.com
- 8Danaher 2016 Annual Reportinvestors.danaher.com
- 9FDA authorizes Xpert Xpress SARS-CoV-2fda.gov
- 10FDA historical EUA informationfda.gov
- 11FDA revocation letter for Xpert Xpress SARS-CoV-2fda.gov
- 12WHO lists additional mpox diagnostic tests for emergency usewho.int
- 13Global Fund briefing note on Cepheid GeneXpert TB testingtheglobalfund.org
- 14UNITAID TBXpert projectunitaid.org
- 15Cepheid antimicrobial-resistance consortium announcementcepheid.mediaroom.com
- 16Cepheid SEC 2015 annual reportsec.gov
- 17Cepheid is incorporatedsec.gov
- 18Reagent Bead Dispenser receives design recognitionen.wikipedia.org
- 19GeneXpert Omni announcedpmc.ncbi.nlm.nih.gov
- 20US medtech acquires UCD spin-out OncoMarksiliconrepublic.com
Cite this profile: Cite the canonical profile. /brand-wiki/cepheid · Editorial policy · How profiles are compiled